FK-506 prevents diabetes in diabetes-prone BB/Wor rats

Ferdinando Nicoletti, Pier Luigi Meroni, Wilma Barcellini, Sebastiano Grasso, Mario Orietta Borghi, Michele Lunett, Roberto Di Marco, Stefania Stefani, Lanfranco Mughini

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The effect of the immunosuppressant FK-506 on the development of diabetes in BB/Wor rats was investigated. Using a treatment schedule (25 μg i.m. from day 27 to 120), not associated with detectable general ill effects, this drug was found to completely inhibit the appearance hyperglycemia and to reduce the histological signs of pancreatic insulitis. The treatment was also able to reduce the percentages of Ia + T-lymphocytes and to block the appearance of detectable serum levels of gamma interferon (IFN).

Original languageEnglish
Pages (from-to)1027-1030
Number of pages4
JournalInternational Journal of Immunopharmacology
Volume13
Issue number7
DOIs
Publication statusPublished - 1991

Fingerprint

Inbred BB Rats
Tacrolimus
Immunosuppressive Agents
Hyperglycemia
Interferon-gamma
Appointments and Schedules
T-Lymphocytes
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

FK-506 prevents diabetes in diabetes-prone BB/Wor rats. / Nicoletti, Ferdinando; Meroni, Pier Luigi; Barcellini, Wilma; Grasso, Sebastiano; Borghi, Mario Orietta; Lunett, Michele; Di Marco, Roberto; Stefani, Stefania; Mughini, Lanfranco.

In: International Journal of Immunopharmacology, Vol. 13, No. 7, 1991, p. 1027-1030.

Research output: Contribution to journalArticle

Nicoletti, Ferdinando ; Meroni, Pier Luigi ; Barcellini, Wilma ; Grasso, Sebastiano ; Borghi, Mario Orietta ; Lunett, Michele ; Di Marco, Roberto ; Stefani, Stefania ; Mughini, Lanfranco. / FK-506 prevents diabetes in diabetes-prone BB/Wor rats. In: International Journal of Immunopharmacology. 1991 ; Vol. 13, No. 7. pp. 1027-1030.
@article{23de72b55f454686b5a0d7436e470746,
title = "FK-506 prevents diabetes in diabetes-prone BB/Wor rats",
abstract = "The effect of the immunosuppressant FK-506 on the development of diabetes in BB/Wor rats was investigated. Using a treatment schedule (25 μg i.m. from day 27 to 120), not associated with detectable general ill effects, this drug was found to completely inhibit the appearance hyperglycemia and to reduce the histological signs of pancreatic insulitis. The treatment was also able to reduce the percentages of Ia + T-lymphocytes and to block the appearance of detectable serum levels of gamma interferon (IFN).",
author = "Ferdinando Nicoletti and Meroni, {Pier Luigi} and Wilma Barcellini and Sebastiano Grasso and Borghi, {Mario Orietta} and Michele Lunett and {Di Marco}, Roberto and Stefania Stefani and Lanfranco Mughini",
year = "1991",
doi = "10.1016/0192-0561(91)90057-E",
language = "English",
volume = "13",
pages = "1027--1030",
journal = "International Journal of Immunopharmacology",
issn = "0192-0561",
publisher = "Elsevier BV",
number = "7",

}

TY - JOUR

T1 - FK-506 prevents diabetes in diabetes-prone BB/Wor rats

AU - Nicoletti, Ferdinando

AU - Meroni, Pier Luigi

AU - Barcellini, Wilma

AU - Grasso, Sebastiano

AU - Borghi, Mario Orietta

AU - Lunett, Michele

AU - Di Marco, Roberto

AU - Stefani, Stefania

AU - Mughini, Lanfranco

PY - 1991

Y1 - 1991

N2 - The effect of the immunosuppressant FK-506 on the development of diabetes in BB/Wor rats was investigated. Using a treatment schedule (25 μg i.m. from day 27 to 120), not associated with detectable general ill effects, this drug was found to completely inhibit the appearance hyperglycemia and to reduce the histological signs of pancreatic insulitis. The treatment was also able to reduce the percentages of Ia + T-lymphocytes and to block the appearance of detectable serum levels of gamma interferon (IFN).

AB - The effect of the immunosuppressant FK-506 on the development of diabetes in BB/Wor rats was investigated. Using a treatment schedule (25 μg i.m. from day 27 to 120), not associated with detectable general ill effects, this drug was found to completely inhibit the appearance hyperglycemia and to reduce the histological signs of pancreatic insulitis. The treatment was also able to reduce the percentages of Ia + T-lymphocytes and to block the appearance of detectable serum levels of gamma interferon (IFN).

UR - http://www.scopus.com/inward/record.url?scp=0026056477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026056477&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(91)90057-E

DO - 10.1016/0192-0561(91)90057-E

M3 - Article

C2 - 1722192

AN - SCOPUS:0026056477

VL - 13

SP - 1027

EP - 1030

JO - International Journal of Immunopharmacology

JF - International Journal of Immunopharmacology

SN - 0192-0561

IS - 7

ER -